(Q37387935)

20 August 2017

1 reference

title

What can be learned from open direct comparative trials in multiple sclerosis? (English)

1 reference

20 August 2017

0 references

Omar Khan

1

1 reference

20 August 2017

publication date

1 February 2009

1 reference

Journal of the Neurological Sciences

20 August 2017

published in

1 reference

20 August 2017

volume

277 Suppl 1

1 reference

20 August 2017

page(s)

S25-8

1 reference

A comparison of observational studies and randomized, controlled trials

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Randomized, controlled trials, observational studies, and the hierarchy of research designs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Systematic reviews in health care: Assessing the quality of controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Observational versus experimental studies: what's the evidence for a hierarchy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970008-5

10.1016/S0022-510X(09)70008-5

7 January 2021

Identifiers

DOI

1 reference

release_b7xmcnmwsrcknpmsfpigf3qtse

20 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b7xmcnmwsrcknpmsfpigf3qtse

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference